Molecular Targeting Technologies,Inc

Reflecting on our time in Toronto at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024: Thanks to Prof. Humphrey Fonge and his team from the University of Saskatchewan, recently moved to Universitè Laval, for their presentation on225Ac-EBTATE.??We noted earlier that they showed real improvement over 225Ac-DOTATATE in mice (complete remission in 80% of mice, 100% survival and similar tumor inhibition with 60% less administered radioactivity). Stacking the combined benefits of our Evans blue long-acting radiotherapeutic platform and 225Ac does set us apart. Explosive growth in targeted radiotherapeutics was more than evident in the number of exhibits and sometimes surprising booth traffic and discussions with practitioners, potential strategic partners and market analysts. Thanks to all of you. And, thanks, as always, to Catherine Lamb of SNMMI for her engagement and support.

https://lnkd.in/eY3Y8frr MTTI PRESENTS AT GBM DRUG DEVELOPMENT SUMMIT Dr. Chris Pak, Molecular Targeting Technologies,Inc , Founder and CEO, is presenting “Overcoming TRP Challenges in GBM Therapy with an Albumin Binding Radiopharmaceutical” at the Glioblastoma Drug Development Summit at 4:15 PM today. The summit presents broad ranging talks from industry thought leaders on diagnosis, trials, tumor microenvironment, BBB transport and, ultimately, innovative treatments. MTTI is excited to share our results on Evans blue enhanced targeted radiopharmaceuticals and the clear benefits of our EvaThera Theranostics platform’s albumin residence, extending?blood half-life, improving safety and efficacy.? Chris will present results of our studies in EBRGD targeting highly expressed Integrin αvβ3 in GBM?and the potential for EBTATE targeting SSTR2 in low grade gliomas.

225Ac-EBTATE HIGHLY EFFECTIVE AGAINST NEUROENDOCRINE TUMORS Molecular Targeting Technologies,Inc , Inc?just published a breakthrough preclinical study of 225Ac-EBTATE vs. NET cancers in the European Journal of Nuclear Medicine, “Long acting 225Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive neuroendocrine tumors”. https://rdcu.be/d2lCG Professor Humphrey Fonge (Universitè de Laval), lead author, commented, “At just 40 % of the administered dose reported for 225Ac-DOTATATE, 225Ac-EBTATE produces enhanced anti-tumor efficacy in Small Cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as shown with complete tumor remissions….We demonstrated that 225Ac-EBTATE was effective against human small-cell lung cancer (SCLC) with 80% complete remission and 100% survival in preclinical models.” MTTI licensed commercial use rights for the patented Evans blue (EB) platform technology from NIBIB (@NIH). It is the basis for our best-in-class, new generation, collection of targeted radiopharmaceuticals (TRP). ? EB binds to serum albumin, extending in vivo circulatory half-life and tumor residence time, enhancing up to 30-fold uptake at a tumor and enabling good efficacy with only 40%?radiopharmaceutical activity and fewer dosing cycles vs. the current SOC. This work parallels MTTI's earlier 3-year follow up of 177Lu-EBTATE in patients (N=30) with metastatic neuroendocrine tumors.?That demonstrated good safety with no nephro- or hepatoxicity and 86% disease control rate using only 40% of the administered radioactivity of 177Lu-DOTATATE. Dr. @Jean-Mathieu Beauregard, MD, Associate Professor of Department of Radiology of Université Laval, said,?“I am encouraged to see the positive results of 225Ac-EBTATE in treating small cell lung cancer and Pan-neuroendocrine tumor (NET) in preclinical studies.?I look forward to working with MTTI and Professor Fonge to translate this into the clinic.”

https://lnkd.in/ezRdpPc7" Fast-Acting, Sprayable Diagnostic for Real-Time Fluorescence-Guided Cytoreductive Surgery Building on our legacy of innovative targeted diagnostics and therapeutics, Molecular Targeting Technologies,Inc recently reported on its topical, near-infrared fluorescent dye, CypH-11 (#Cmetglo) at the World Molecular Imaging Conference (WMIC) meeting in Montreal and at the Peritoneal Surface Oncology Group International (PSOGI) meeting in Lyon. This technology shows promise as a real-time tool for oncologists in fluorescence-guided surgery (#FGS). Clinicians can see small tumor residue quickly, driving a more complete resection of cancers. #Cmetglo improves patient outcomes, avoiding normal tissue damage and improving progression-free survival. Summarizing comments by Dr. Johnny Ong, MD, Associate Professor, Department of Sarcoma, Peritoneal and Rare Tumors, National Cancer Centre Singapore; Dr. Brian D Gray, SVP Research and Development at MTTI and Dr. Seung Koo Lee, Assistant Professor of Cell Biology Research, in Radiology at Weill Cornell Medicine: “MTTI’s Cmetglo makes the invisible immediately visible. Tumor margins and metastases glow under near-infrared light enhancing a surgeon’s ability to differentiate between normal and scar tissues in cytoreductive surgery (CRS). Cmetglo is a sprayable,?pH-responsive probe, fluorescing brightly in an acidic tumor microenvironment, a universal signature of cancer cell proliferation. It readily detects small ovarian and colorectal tumors. We're targeting these malignancies as best clinical use of Cmetglo, later expanding to other histological subtypes.”

Molecular Targeting Technologies,Inc congratulates our collaborator Prof. Humphrey Fonge on his recent move to New Hospital Complex (NCH) of the?Centre de recherche du CHU de Québec-Université Laval.?Prof. Fonge continues to be instrumental in MTTI’s development of 225Ac-EBTATE? for SSTR2 expressing solid tumors.? #EBTATE?, an EvaThera Theranostics platform therapeutic, is a new, long-acting SSTR2, radiotherapeutic for neuroendocrine and other tumors.?A conjugated Evans blue moiety binds to serum albumin, extending in vivo residence time. Fewer treatment cycles and lower doses expose the patient to <40% of the total radiation of the current standard of care while delivering similar outcomes. Professor Fonge is a full professor at the Faculty of Pharmacy. He began his academic career in 2013 at the College of Medicine at the University of Saskatchewan,?completed his PhD in radiopharmacy at Katholieke Universiteit Leuven in Belgium and an MBA and postdoctoral training in theranostics and drug administration at the University of Toronto. His research centers on developing, evaluating and translating new anticancer theranostic agents into clinical trials and studying changes in the tumor microenvironment caused by radiopharmaceuticals or antibody-drug conjugates in various cancers.

https://lnkd.in/ehd3QtSz MTTI reports on 225Ac-EBTATE at SNMMI Toronto MTTI will update findings on both?177Lu-EBTATE clinical and?225Ac-EBTATE preclinical work at SNMMI 2024 ?in Toronto (Booth#1819) Our ?EvaTheratm drug platform exploits Evans blue albumin binding to extend?in vivo?circulatory half-life and tumor residence time, enabling effective use of significantly lower radiopharmaceutical activity and fewer dosing cycles vs. faster clearing ?PRRTs. 225Ac-EBTATE was effective against SCLC with 80% complete remissions and 100% survival. at 60% less administered radioactivity than 225Ac-DOTATATE and was well tolerated. Stop by and meet our team

https://lnkd.in/ehd3QtSz MTTI reports on 225Ac-EBTATE at SNMMI Toronto MTTI will update findings on both?177Lu-EBTATE clinical and?225Ac-EBTATE preclinical work at SNMMI 2024?in Toronto (Booth#1819) Our ?EvaThera drug platform exploits Evans blue albumin binding to extend?in vivo?circulatory half-life and tumor residence time, enabling effective use of significantly lower radiopharmaceutical activity and fewer dosing cycles vs. faster clearing PRRTs. 225Ac-EBTATE was effective against SCLC with 80% complete remissions and 100% survival. at 60% less administered radioactivity than 225Ac-DOTATATE and was well tolerated. Stop by and meet our team?